Log In
BCIQ
Print this Print this
 

ibalizumab (TMB-355) (formerly TNX-355)

Also known as: formerly Hu5A8

  Manage Alerts
Collapse Summary General Information
Company Genentech Inc.
DescriptionHuman mAb against CD4 that prevents viral entry
Molecular Target CD4
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase III
Standard IndicationHIV / AIDS
Indication DetailsTreat HIV infection; Treat HIV-1 infection in patients refractory to antiretroviral therapy (ART); Treat multidrug-resistant HIV-1 infection in treatment-experienced patients
Regulatory Designation U.S. - Breakthrough Therapy (Treat HIV infection);
U.S. - Orphan Drug (Treat HIV infection);
U.S. - Priority Review (Treat HIV infection)
PartnerRoche;
TaiMed Biologics Inc.;
Theratechnologies Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$170.5M

$1.0M

$168.5M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/18/2016

$170.5M

$1.0M

$168.5M

Get a free BioCentury trial today